Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane

Neoplasma

Volumn 56, Issue 6, 2009, Pages 548-556

  Hunakova, L ^a   Sedlakova, O ^b   Cholujova, D ^a   Gronesova, P ^a   Duraj, J ^a   Sedlak, J ^a  

^a Cancer Research Institute   (Slovakia)

^b INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Breast cancer; Cytokine production; EMT; Matrix metalloproteinases; Reversal of aggressiveness; Sulforaphane

Indexed keywords

BENZODIAZEPINE RECEPTOR; CARBONATE DEHYDRATASE IX; GAMMA INTERFERON; GELATINASE B; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR; STROMELYSIN; SULFORAPHANE; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIMENTIN; ANTINEOPLASTIC AGENT; CYTOKINE; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIOCYANATES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 70449727214     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_06_548     Document Type: Article

References (40)

1. WU XZ. New strategy of antiangiogenic therapy for hepatocellular carcinoma Minireview. Neoplasma 2008; 55: 472-481.
2. HERAK BM, BAGO R, KONJEVODA P et al. Gene expression profiling of Nm23-H2 overexpressing CAL 27 cells using DNA microarray. Neoplasma 2008; 55: 447-454.
3. KOHRMANN A, KAMMERER U, KAPP M et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009; 9: 188- doi:10.1186/1471-2407-9-188
4. HOLLIER BG, EVANS K, MANI SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009; 14: 29-43. doi:10.1007/s10911-009-9110-3
5. BUHLER H, SCHALLER G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 2005; 3: 365-371. doi:10.1158/1541-7786.MCR-04-0117
6. HUBER MA, KRAUT N, BEUG H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558. doi:10.1016/j.ceb.2005.08.001
7. ZANG S, JI C, QU X et al. A study on Notch signaling in human breast cancer. Neoplasma 2007; 54: 304-310.
8. ANSIEAU S, BASTID J, DOREAU A et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79-89. doi:10.1016/j.ccr.2008.06.005
9. VALDES-MORA F, GOMEZ DEL PT, BANDRES E et al. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol 2009; 16: 78-87. doi:10.1245/s10434-008-0166-x
10. GORT EH, SUIJKERBUIJK KP, ROOTHAAN SM et al. Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3325-3330. doi:10.1158/1055-9965.EPI-08-0472
11. ALTANER C. Glioblastoma and stem cells. Neoplasma 2008; 55: 369-374.
12. CHANG CC, SHIEH GS, WU P et al. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res 2008; 68: 6281-6291. doi:10.1158/0008-5472.CAN-08-0094
13. PASTOREKOVA S, PARKKILA S, PASTOREK J et al. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229. doi:10.1080/14756360410001689540
14. LAKOTA J, SKULTETY L, DUBROVCAKOVA M et al. Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis. Neoplasma 2008; 55: 488-492.
15. HOLOTNAKOVA T, ZIEGELHOFFER A, OHRADANOVA A et al. Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes. Pflugers Arch 2008; 456: 323-337. doi:10.1007/s00424-007-0400-6
16. HUNAKOVA L, BODO J, CHOVANCOVA J et al. Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 2007; 54: 541-548.
17. NIAN H, DELAGE B, HO E et al. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 2009; 50: 213-221. doi:10.1002/em.20454
18. MYZAK MC, DASHWOOD RH. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett 2006; 233: 208-218. doi:10.1016/j.canlet.2005.02.033
19. AZARENKO O, OKOUNEVA T, SINGLETARY KW et al. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis 2008; 29: 2360-2368. doi:10.1093/carcin/bgn241
20. PLEDGIE-TRACY A, SOBOLEWSKI MD, DAVIDSON NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 2007; 6: 1013-1021. doi:10.1158/1535-7163.MCT-06-0494
21. DUSSOSSOY D, CARAYON P, FERAUT D et al. Development of a monoclonal antibody to immuno-cytochemical analysis of the cellular localization of the peripheral benzodiazepine receptor. Cytometry 1996; 24: 39-48. doi:10.1002/(SICI)1097-0320(19960501)24:1〈39::AID-CYTO5〉3.0.CO;2-D
22. GALIEGUE S, CASELLAS P, KRAMAR A et al. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res 2004; 10: 2058-2064. doi:10.1158/1078-0432.CCR- 03-0988
23. PASTOREKOVA S, ZAVADOVA Z, KOSTAL M et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 620-626. doi:10.1016/0042-6822(92)90464-Z
24. SULLIVAN NJ, SASSER AK, AXEL AE et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009;
25. STASINOPOULOS I, O'BRIEN DR, BHUJWALLA ZM. Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. Cancer Biol Ther 2009; 8: 31-35.
26. WILSON TJ, NANNURU KC, FUTAKUCHI M et al. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008; 68: 5803-5811. doi:10.1158/0008-5472.CAN- 07-5889
27. WANG F, REIERSTAD S, FISHMAN DA. Matrilysin overexpression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006; 236: 292-301. doi:10.1016/j.canlet.2005.05.042
28. YOSHIDA S, TAKAHASHI H. Expression of extracellular matrix molecules in brain metastasis. J Surg Oncol 2009; 100: 65-68. doi:10.1002/jso.21296
29. TAI MH, CHANG CC, KIUPEL M et al. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26: 495-502. doi:10.1093/carcin/bgh321
30. WANG P, BRANCH DR, BALI M et al. The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. Biochem J 2003; 375: 199-205. doi:10.1042/BJ20030579
31. FRASOR J, WEAVER AE, PRADHAN M et al. Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 2008; 149: 6272-6279. doi:10.1210/en.2008-0352
32. GORDON AH, O'KEEFE RJ, SCHWARZ EM et al. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res 2005; 65: 3209-3217.
33. HEISS E, HERHAUS C, KLIMO K et al. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276: 32008-32015. doi:10.1074/jbc.M104794200
34. MOON DO, KIM MO, KANG SH et al. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett 2009; 274: 132-142. doi:10.1016/j.canlet.2008.09.013
35. WANG Z, KONG D, BANERJEE S et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 2007; 67: 11377-11385. doi:10.1158/0008-5472.CAN-07-2803
36. CHO NP, HAN HS, LEEM DH et al. Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. Oral Oncol 2009; 45: 654-660. doi:10.1016/j.oraloncology.2008.07.003
37. HU M, PELUFFO G, CHEN H et al. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009; 106: 3372-3377. doi:10.1073/pnas.0813306106
38. TELANG U, BRAZEAU DA, MORRIS ME. Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells. Exp Biol Med (Maywood) 2009; 234: 287-295. doi:10.3181/0808-RM-241
39. NIAN H, DELAGE B, HO E et al. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 2009; 50: 213-221. doi:10.1002/em.20454
40. SHAN B, YAO TP, NGUYEN HT et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008; 283: 21065-21073. doi:10.1074/jbc.M802786200